Favipiravir, also called T 705,which is a pyrazinecarboxamide derivative with activity against RNA viruses. Favipiravir is converted to the ribofuranosyltriphosphate derivative by host enzymes and selectively inhibits the influenza viral RNA-dependent RNA polymerase.On the base of Favipiravir mechanism, It often treat influenza in Japan and it was also being studied to treat a number of other viral infections.Especially for coronavirus(COVID-2019), Favipiravir was approved for treatment of COVID-2019 by China, Japan, Russia,Korea, India…. After several clinical trials at different countries, this drug has shown very positive results.
|Appearance||Yellowish to off – white crystalline powder||Purity||98%|
For research use only
|COA & NMR||Download||MSDS||Download|
 Koons C (7 August 2014). “Ebola Drug From Japan May Emerge Among Key Candidates”. Bloomberg.com.
 Fink S (4 February 2015). “Ebola Drug Aids Some in a Study in West Africa”. The New York Times.
 Lumby, Casper (3 March 2020). “Favipiravir and Zanamivir Cleared Infection with Influenza B in a Severely Immunocompromised Child”. Clinical Infectious Diseases. Retrieved 5 May 2020.
 EJ Lane (June 22, 2016). “Fujifilm in Avigan API license with Zhejiang Hisun Pharmaceuticals”. Fierce Pharma. Retrieved April 20, 2020.
”Medicine registration license ЛП-006225″. Government registry of medicines. Russian Ministry of Health. Retrieved May 30, 2020.